Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Anthera Selects the Merck BioManufacturing Network to Supply A-623, Anthera’s Investigational Novel Peptibody Agent

By Pharmaceutical Processing | December 15, 2010

Anthera Pharmaceuticals, Inc., a biopharmaceutical company
developing drugs to treat serious diseases associated with abnormal auto-immune
responses and inflammation, has selected the Merck BioManufacturing Network in
the UK,
to manufacture the large scale GMP clinical and pre-commercial supplies of
A-623, an investigational novel peptibody in development for a number of
autoimmune diseases.

“Establishing a rapid and high quality supply of A-623
for our current and future clinical programs is a critical element of our
strategic plan and provides a number of potential development options,”
stated Paul F. Truex, President and Chief Executive Officer of Anthera.
“The selection of the Merck BioManufacturing Network provides world-class,
large molecule manufacturing capabilities at all stages of production with the
necessary expertise to accelerate the development of A-623 in Systemic Lupus
Erythematosus and other autoimmune diseases.”

Steve Bagshaw, Site General Manager of the Merck
BioManufacturing Network, said, “We are delighted that Anthera has chosen
to work with us, recognizing our many years of development experience in
microbial biologics and our capacity that offers appropriate scales for their
manufacturing needs.”   A-623 will be manufactured in the Billingham,
UK
facility of the Network.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE